Fexlamose is being developed as a chronic treatment for COPD and asthma in conjunction with standard therapies, to improve ...

Part B of the LIGHTHOUSE study will enroll adults and children. DURHAM, N.C., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a clinical-stage gene therapy company focused ...

Ownership structure can significantly affect performance, profitability and other business outcomes, research shows. As ...